Form 4: NeueHealth CFO Jay Matushak Awarded Restricted Stock Units

Chief Financial Officer of NeueHealth, Jay Matushak, reports the acquisition of restricted stock units following shareholder approval of an amendment to the company's incentive plan.

Summary

• Jay Matushak, CFO of NeueHealth, filed a Form 4 disclosing the acquisition of restricted stock units.
• On May 2, 2024, Matushak was granted 72,000 restricted stock units that vest in three equal annual installments beginning on March 11, 2025.
• Additionally, Matushak was granted 180,000 restricted stock units that vest 100% on October 11, 2026.
• The grants were initially approved by the Issuer's Compensation and Human Capital Committee on March 11, 2024, and October 11, 2023, respectively, and were subject to shareholder approval of an amendment to the Issuer's Amended and Restated 2021 Omnibus Incentive Plan, which was obtained on May 2, 2024.
• Each restricted stock unit represents a contingent right to receive one share of NeueHealth's common stock.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, suggesting stability and alignment of interests. The vesting schedules promote long-term commitment.

Positives

• The granting of restricted stock units aligns the CFO's interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the CFO.

Future Outlook

The restricted stock units are subject to vesting schedules, incentivizing the CFO's continued service and alignment with shareholder interests.

Industry Context

Granting restricted stock units to key executives is a common practice to incentivize performance and retain talent in the healthcare industry.

Stakeholder Impact

• Shareholders may view the granting of restricted stock units positively as it aligns management's interests with long-term company performance.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates